NCT05074823View on ClinicalTrials.gov

Comparing Three Different Doses of Intrathecal Ketamine

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 26, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 11, 2023

Conditions
Ketamine Causing Adverse Effects in Therapeutic Use
Interventions
DRUG

Ketamine 0.1 mg

Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg

DRUG

Ketamine 0.2 mg

will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg

DRUG

Ketamine 0.3 mg

will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg

Trial Locations (1)

11111

Assiut University hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER